Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Cash from Financing Activities (2016 - 2025)

Assembly Biosciences (ASMB) has 11 years of Cash from Financing Activities data on record, last reported at $171.9 million in Q3 2025.

  • For Q3 2025, Cash from Financing Activities changed N/A year-over-year to $171.9 million; the TTM value through Sep 2025 reached $191.2 million, up 783.33%, while the annual FY2024 figure was $29.4 million, 113.12% up from the prior year.
  • Cash from Financing Activities reached $171.9 million in Q3 2025 per ASMB's latest filing, up from $357000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $171.9 million in Q3 2025 and bottomed at $134000.0 in Q2 2023.
  • Average Cash from Financing Activities over 5 years is $19.4 million, with a median of $5.3 million recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: soared 28586.55% in 2021, then plummeted 97.13% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $2.7 million in 2021, then plummeted by 83.89% to $437000.0 in 2022, then skyrocketed by 2003.43% to $9.2 million in 2023, then skyrocketed by 84.89% to $17.0 million in 2024, then surged by 911.66% to $171.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $171.9 million in Q3 2025, $357000.0 in Q2 2025, and $1.9 million in Q1 2025.